Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women

Menopause

Volumn 15, Issue 2, 2008, Pages 369-373

  Prezelj, Janez ^a   Ostanek, Barbara ^b   Logar, Darja Bitenc ^b   Marc, Janja ^b   Hawa, Gerhard ^c   Kocjan, Tomas ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c Research and Development Department   (Austria)

Author keywords

Bone turnover marker; C terminal cross linking telopeptide of type I collagen; Osteocalcin; Osteoporosis; Osteoprotegerin; Receptor activator of nuclear factor B ligand

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOPROTEGERIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FEMUR NECK; HUMAN; OSTEOPENIA; POSTMENOPAUSE;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CATHEPSINS; COLLAGEN TYPE I; FEMALE; FEMUR NECK; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPROTEGERIN; PEPTIDES; PERIMENOPAUSE; POSTMENOPAUSE; RANK LIGAND;

EID: 40449096333     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181271873     Document Type: Article

References (30)

1. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-3371.
2. Krall EA, Dawson-Hughes B, Hirst K, et al. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J Gerontol A Biol Sci Med Sci 1997;52:M61-M67.
3. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-1245.
4. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-480.
5. Marcus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-1595.
6. Reyes R, Fernandez-Garcia DM, De la Higuera M. Serum cathepsin K: a novel bone resorption marker in the evaluation of postmenopausal women treated with alendronate. Bone 2005;36:S296.
7. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-32352.
8. Bromme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995;376:379-384.
9. Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-1238.
10. Kiviranta R, Morko J, Uusitalo H, et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001;16:1444-1452.
11. Stroup GB, Lark MW, Veber DF, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001;16:1739-1746.
12. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int 1996;6:256-261.
13. Morko J, Kiviranta R, Hurme S, et al. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 2005;36:854-865.
14. Chaki O, Yoshikata I, Kikuchi R, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 2000;15:1537-1544.
15. Donescu OS, Battie MC, Videman T, et al. The predictive role of bone turnover markers for BMD in middle-aged men. Aging Male 2006;9:97-102.
16. Atley LM, Mort JS, Lalumiere M, et al. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 2000;26:241-247.
17. Holzer G, Noske H, Lang T, et al. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 2005;146:13-17.
18. Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 2006;52:1-10.
19. Shan PF, Wu XP, Zhang H, et al. Age-related changes of serum bone alkaline phosphatase and cross-linked C-telopeptides of type I collagen and the relationship with bone mineral density in Chinese women. Clin Chim Acta 2006;366:233-238.
20. Pi YZ, Wu XP, Liu SP, et al. Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab 2006;24:380-385.
21. Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-1091.
22. Kerschan-Schindl K, Hawa G, Kudlacek S, et al. Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 2005;40:532-535.
23. Pang M, Martinez AF, Jacobs J, et al. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in preosteoclastic cells. Biochem Biophys Res Commun 2005;328:756-763.
24. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
25. Corisdeo S, Gyda M, Zaidi M, et al. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun 2001;285:335-339.
26. Wittrant Y, Theoleyre S, Couillaud S, et al. Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun 2003;310:774-778.
27. Hakeda Y, Kobayashi Y, Yamaguchi K, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 1998;251:796-801.
28. Yasuda Y, Kaleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005;57:973-993.
29. Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
30. Hawa G, Brinskelle-Schmal N, Glatz K, et al. Immunoassay for soluble RANKL (receptor activator of NF-κB ligand) in serum. Clin Lab 2003;49:461-463.